A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.

Trial Details

NCT ID
NCT04503265
Phase
PHASE1 / PHASE2
Sponsor
AtlasMedx, Incorporated
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • AMXI-5001:Dose Escalation Phase I
  • AMXI-5001:Dose Expansion Phase II
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
  • Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
  • Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
  • Malignancy has progressed after standard therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →